KOVE Medical – Amniosnare: Making Fetal Surgery Safer with Innovative Amniotic Membrane Suturing
The Problem
Fetal surgery can save lives before birth, but it leaves a hidden risk behind. Around 800,000 fetuses are affected by congenital conditions such as spina bifida each year. Minimally invasive fetal surgery can treat some of them in the womb, but the small puncture it leaves in the amniotic sac cannot currently be closed and does not heal on its own. This open defect can cause the membrane to rupture or leak, leading to premature birth in up to 80% of cases and putting both babies and mothers at risk.
The Project
What if surgeons could close the gap at the end of every fetal surgery? KOVE Medical is developing a suturing device designed specifically for fetal surgery. It closes the fetal membrane through the same small (≈3.6 mm) access port used during the procedure, creating a secure, minimally invasive closure.
In preclinical studies in pregnant sheep, KOVE successfully closed 20 of 22 defects (91%), all closures remained watertight until the end of the study, and mothers and fetuses were safe.
The Impact
KOVE’s innovation could make fetal surgery safer for both babies and mothers, reducing the risk of preterm birth and pregnancy complications, and helping more families benefit from treatment before birth. By preventing prematurity, the device could also ease the pressure on neonatal intensive care and healthcare systems, while advancing a new category of intrauterine care.
The Result
With the support of Evolution Europe, KOVE Medical secured €1.26 million in funding from Innosuisse, the Swiss Innovation Agency, through its Start-up Innovation Projects programme. This funding will support a first-in-human study and a safety clinical trial, bringing KOVE towards US market approval through the Humanitarian Device Exemption pathway.